P4E6 cell line

Prostate cancer well differentiated, early stage

STR-PCR Data:

Amelogenin: X
CSF1PO: 12
D13S317: 11
D16S539: 11
D5S818: 12
D7S820: 7,8
THO1: 7,9.3
TPOX: 8
vWA: 17,19

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at approximately 3 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. It is important to inactivate the trypsin with an equal volume of trypsin inhibitor (the culture medium contains too low a serum content to inactivate the trypsin). To remove all traces of trypsin and trypsin inhibitor pellet the cells by centrifugation and resuspend the cells in fresh medium. Media change every second day.

Stemline Keratinocyte Medium II (Sigma S0196) + Stemline Keratinocyte Growth Supplement (Sigma S9945) + 2 mM Glutamine + 2% Fetal Bovine Serum (FBS). Addition of 2% serum was found to increase cell viability.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by cellscreening@merckgroup.com to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form. Additionally, any recipient wanting to use the cell line in the field of vaccines for the treatment or prevention of prostate cancer should first obtain permission from GemVax & KAEL Co., Ltd. Contact : Dr. Eujin Hyun, Head of R&D Department (eujinhyun@kaelgemvax.com).